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Abstract
Background: Membrane androgen receptors (mAR) have been implicated in the regulation of cell
growth, motility and apoptosis in prostate and breast cancer. Here we analyzed mAR expression
and function in colon cancer.
Results: Using fluorescent mAR ligands we showed specific membrane staining in colon cell lines
and mouse xenograft tumor tissues, while membrane staining was undetectable in healthy mouse
colon tissues and non-transformed intestinal cells. Saturation/displacement assays revealed time-
and concentration-dependent specific binding for testosterone with a KD of 2.9 nM. Stimulation of
colon mAR by testosterone albumin conjugates induced rapid cytoskeleton reorganization and
apoptotic responses, even in the presence of anti-androgens. The actin cytoskeleton drug
cytochalasin B effectively inhibited the pro-apoptotic responses and caspase-3 activation.
Interestingly, in vivo studies revealed that mAR activation resulted in a 65% reduction of tumor
incidence in chemically induced Balb/c mice colon tumors.
Conclusion: Our results demonstrate for the first time that functional mARs are predominantly
expressed in colon tumors and that their activation results in induction of anti-tumor responses in
vitro and extensive reduction of tumor incidence in vivo.
Introduction
Scientific evidence accumulated in recent years points to
the existence of membrane androgen receptors (mAR),
triggering rapid, non-genomic signals. Although the exact
molecular identity of mAR still remains unknown, non-
genomic androgen actions manifested within minutes
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have been reported in various cell types including macro-
phages and T cells [1,2], LNCaP [3,4], T47D [5], MCF7
[6], DU145 [7-9], C6 [10], PC12 [11] or VSMC cells [12].
These effects are clearly different from those manifested
upon activation of the intracellular androgen receptors
(iAR) mediating genomic androgen signals resulting in
receptor dimerization, nuclear translocation and subse-
quent activation of androgen-specific target genes
(reviewed in [13]).
The mAR-dependent signaling was recently characterized
in detail in prostate and breast cancer cell lines (reviewed
in [14-17]). Using non-permeable androgen derivatives
that do not bind to iAR, it was shown that mAR activation
resulted in actin reorganization regulated by mechanisms
involving small GTPases [8,18]. Furthermore, it was
shown that mAR activation induced profound apoptotic
regression of prostate cancer cells in vitro and in mouse
xenografts in vivo [7,19] and suppressed cell growth and
motility [6,19]. Finally, most recent studies have impli-
cated key pro-survival and pro-apoptotic gene products
such as AKT, NF-κB, Bad, Fas and caspase-3 in the regula-
tion of the apoptotic response induced by mAR activation
in prostate cancer cells [9].
Taken together, these studies clearly established that func-
tional mARs trigger strong anti-tumorigenic effects, imply-
ing a potential role of mAR as a novel target for the
development of selective cancer treatments (reviewed in
[17]). However, it remained elusive whether mARs are
also expressed in other tumors and whether their activa-
tion could result in the induction of anti-tumorigenic
effects similar to the ones described in prostate and breast
cancer cells. Colon tissues are known to express functional
nuclear hormone receptors (reviewed in [20]), and spe-
cific AR, ERα and ERβ genotypes have been associated
with colon cancer [21]. Moreover, administration of
androgens has been linked to the promotion of colon can-
cer tumorigenesis in rats [22]. On the other hand, steroid
hormones induced tumor growth remission in xenotrans-
planted adenocarcinomas in nude mice [23], arguing for
a more complex role of steroid hormones in colon cancer.
Since the membrane androgen receptor, in contrast to the
classical intracellular androgen receptor, induces tumor
regression in target tissues (reviewed in [17]), we sought
to determine the expression and functional status of mAR
in colon cancer. To this end, we used colon cancer tissues
isolated from mice xenograft tumors and from two estab-
lished colon cancer cell lines (Caco2 and HCT116 cells).
As a result, testosterone binding sites were expressed in
the membrane of colon cancer cells and qualify as bona
fide membrane androgen receptors as assessed by radioli-
gand binding studies, Scatchard analysis and displace-
ment assays. The activation of those receptors with non-
permeable testosterone derivatives triggered rapid and
profound actin and tubulin cytoskeleton reorganization
and induced pro-apoptotic responses. Finally, treatment
of Balb/c mice with testosterone albumin conjugates
resulted in considerable anti-tumor activity in vivo. Our
findings provide strong evidence for the anti-tumorigenic
activity of functional mAR in colon cancer both in vitro
and in vivo and further support previous reports on the
clinical significance of mAR targeting for cancer treatment.
Materials and methods
Cell cultures
The Caco2 and HCT116 human colon cancer cell lines
and the non transformed intestinal IEC06 cells were
obtained from the American Type Culture Collection
(Manassas, VA) and were studied between passages 55
and 70.
Preparation of steroid solution
Before each experiment testosterone-3-(O-carboxyme-
thyl)oxime human serum albumin, (testosterone-HSA or
Testo-HSA; Sigma) was dissolved in serum-free culture
medium at a final concentration of 10-5 M. This stock
solution was incubated for 30 min at room temperature
with 0.3% charcoal and 0.03% dextran, centrifuged at
3,000 × g and passed through a 0.45 μm filter to remove
any potential contamination with free steroid. This is
highly important for the interpretation of the results to
disconnect any possible intracellular testosterone- and/or
iAR-interference with the effects mainly induced by the
mAR activation. Testosterone HSA, estradiol and dihy-
drotestosterone (DHT) (Sigma) solutions were used at a
final concentration of 10-7 M throughout the study unless
otherwise mentioned. All treatments and incubations
with steroids including apoptosis assays were performed
in serum-containing medium. Testosterone-HSA-FITC or
control HSA-FITC constructs were generated by conjugat-
ing Testosterone-HSA or HSA with FITC (Sigma) using
standard techniques.
Preparation of paraffin blocks from HCT116 colon cancer 
xenografts
HCT116 cells or p53-deficient HCT116 (HCT116p53-/-
cells, kindly donated by Dr. Vogelstein) were injected sub-
cutaneously at the axillary region of 7-9 weeks old male
SCID (NOD.CB17 Prkdcscid) mice (Jackson Laboratories/
Charles River Laboratories, L'Arbresle, France) according
to the British practice of bilateral trocar implants as
described previously [24]. Each inoculum contained 106
cells exponentially growing at the time of harvesting.
When tumors reached about 1000 mm3 in size, animals
were sacrificed and tumors were excised and fixed in buff-
ered formalin (4%) embedded in paraffin. 4-μm sections
were prepared with the aid of a Leica microtome (model
RM2125). Subsequently, sections were stained with
hematoxylin-eosin and examined under a microscope toMolecular Cancer 2009, 8:114 http://www.molecular-cancer.com/content/8/1/114
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assess the histological phenotype of the tumor, the type
and degree of differentiation, and the presence of regres-
sive changes. Other sections were de-paraffinized and sub-
jected to standard immunofluorescence analysis using
fluorescent Testo-HSA-FITC or HSA-FITC control conju-
gates as described in the following section. All animals
were treated according to the Greek law and the instruc-
tions of the European council (86/609 and ETS123,
respectively) governing the use and handling of animals
in experiments.
Immunofluorescence analysis and confocal laser scanning 
microscopy
Cells were cultured on glass cover slips with testosterone-
HSA-FITC or control HSA-FITC using the concentrations
and the incubation periods indicated in the figure leg-
ends. For testosterone-HSA-FITC staining, cells or speci-
mens were washed twice with PBS containing 1.5% FBS
for 1.5 min and incubated for 1 h with 1% BSA in PBS at
room temperature. After two washes with PBS/1.5% FBS
cells were exposed to 10-7 M testosterone-HSA-FITC, while
control cells were incubated with 4 × 10-7 M HSA-FITC for
1 h at room temperature. Nuclei were stained with
DRAQ5™ (Biostatus Limited) or TO-PRO-3 (Invitrogen).
After two washes with PBS/1.5% FBS and fixation with
0.5% paraformaldehyde for 30 min cells were washed
twice with PBS/1.5% FBS for 3 min and mounted with
slow anti-fade. For direct fluorescence microscopy of F-
actin, cells were fixed with 3% paraformaldehyde in PBS
for 30 min, permeabilized with 0.5% Triton X-100 in PBS
(10 min) and incubated with rhodamine-phalloidin
(Molecular Probes, Eugene, OR, 1:100 dilution) for 40
min in the dark. For indirect immunofluorescence stain-
ing cells were incubated for 2 h at room temperature with
mouse monoclonal anti-tubulin (Cell signaling, 1: 1000
dilution). Secondary FITC-conjugated rabbit anti-mouse
IgG (Invitrogen) was used at a 1:200 dilution. Nuclei were
stained with DRAQ5™ (Biostatus Limited). Slides were
mounted using the ProLang® Gold Antifade reagent (Inv-
itrogen). All specimens were examined with a BH-2
microscope (Olympus Corp., Lake Success, NY) equipped
with epifluorescence illumination. Confocal microscopy
was performed on a Zeiss LSM 5 EXCITER confocal laser-
scanning module (Carl Zeiss, Göttingen, Germany) and
images were analyzed with the software of the instrument.
Binding assays
For membrane preparation Caco2 cells cultured in five
150 cm2 flasks without serum, were washed twice with
PBS, removed by scraping, and centrifuged at 1,500 g for
5 min. Pelleted cells were homogenized by sonication in
50 mM Tris-HCl buffer, pH 7.4, containing freshly added
protease inhibitors (10 μg/ml PMSF and Roche complete
protease inhibitor tablets). Unbroken cells were removed
by centrifugation at 2,500 g for 15 min. Membranes were
obtained by centrifugation at 45,000 g for 1 h and washed
once with the same buffer. Protein concentration was
measured by the method of Bradford using reagents from
Bio-Rad (Hercules, CA).
Binding conditions
Saturation binding experiments were performed in a final
volume of 0.1 ml containing cell membranes at a final
protein concentration of 1.2 mg/ml and at least seven
concentrations of [3H] testosterone (Amersham, GE
Healthcare, United Kingdom) ranging from 2 to 100 nM.
For displacement binding experiments, cell membrane
preparations at a final concentration of 1.2 mg/ml were
incubated with 5 nM [3H] testosterone in the absence or
in the presence of different concentrations of unlabeled
steroid (DHT, estradiol), ranging from 10-12 to 10-6 M.
Non-specific binding was estimated in the presence of 5
μM DHT. In both types of binding experiments, after an
overnight incubation at 4°C, bound radioactivity was sep-
arated by filtration under reduced pressure through GF/A
filters previously soaked in 0.5% polyethylenimine (PEI)
in water and rinsed three times with ice-cold Tris-HCl
buffer. Filters were mixed with 10 ml scintillation cocktail
(03999, Fluka), and bound radioactivity was counted in a
scintillation counter (1415 Liquid Scintillation Counter,
Wallac) with 60% efficiency for Tritium. The KD and Bmax
values for the membrane binding sites were determined
from Scatchard plots based on saturation bindings.
Cell-surface biotinylation and Western blotting
Caco2 cells were washed twice with ice cold PBS and sur-
face biotinylated with 0,5 mg/ml sulfo-NHS-SS-biotin
(Pierce, Rockford, IL) for 30 min at 4°C. Cells were subse-
quently washed twice with PBS and lysed for 1 hour in
RIPA buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1.0 mM
EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0% sodium deox-
ycholate) with protease inhibitors (Roche, Mannheim,
Germany). Then, 500 μg protein was loaded on beads
(Pierce, Rockford, IL) and incubated at 4°C overnight on
a rocking platform. Biotinylated and non- biotinylated
proteins were separated by centrifugation, and samples
were analyzed by SDS-PAGE and immunoblotting. Mem-
branes were incubated overnight at 4°C with affinity puri-
fied rabbit anti-androgen receptor antibody (1:1000
dilution, Cell Signaling, Danvers, MA). Washes in TBST
and subsequent blocking, was followed by incubation
with secondary anti rabbit antibody (1:2000 dilution,
Cell Signaling, Danvers, MA) for 1 h at RT. Blots were
developed with the ECL detection reagent (Amersham,
Freiburg, Germany). For loading controls, blots were
stripped in stripping buffer (Carl Roth, Karlsruhe, Ger-
many) at 56°C for 30 min, washed in TBST and blocked
with 5% milk in TBST for 1 h at RT. After membrane incu-
bation with affinity purified rabbit anti-β-actin antibody
(1:1000 dilution, Cell Signaling, Danvers, MA) or mouseMolecular Cancer 2009, 8:114 http://www.molecular-cancer.com/content/8/1/114
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monoclonal anti-sodium potassium ATPase antibody
(1:5000 dilution, Abcam, Cambridge, UK) and subse-
quent incubation with the respective secondary antibody,
bands were detected with ECL detection reagent.
Measurement of the G/total actin ratio by Triton X-100 
fractionation
The Triton X-100-soluble G-actin-containing and total-
actin-containing fractions of cells exposed to testosterone-
HSA in the presence (1 h pre-treatment) or absence of 10-
7 M cytochalasin B (Biomol Research Laboratories, PA)
were prepared as previously described [25]. A decrease in
the triton-soluble (G-) over the total (T-) actin ratio is
indicative of actin polymerization.
Annexin V staining
Cells were transferred to a staining tube and washed with
4 ml PBS containing 1% BSA at 4°C. After medium
removal, the cell pellet was re-suspended in 200 μl cold
PBS. 5 μl Annexin V-FITC (BD Biosciences) was added and
incubation was carried out for 20 min at 37°C protected
from light. Then, the suspension was transferred onto a
glass slide and mounted with Prolong® Gold antifade rea-
gent (Invitrogen).
APOPercentage apoptosis assay
Caco2 cells (in RPMI 1640, supplemented with 25 mM
HEPES, 2 mM L-Glutamine and 10% FBS) were cultured
in 96-well plates for the APOPercentage apoptosis assay
(Biocolor Ltd., Belfast, Ireland). In the presence or
absence of 10-7 M flutamide, cytochalasin B (Sigma) and
DEVD-fmk, they were stimulated or not for 24 h in serum-
containing medium with 10-7 M of the following steroids:
testosterone-HSA, dihydrotestosterone (DHT) and estra-
diol (E2). Untreated cells cultured in serum-free medium
were used as positive control for apoptosis.
Caspase-3 assay
The activity of caspase-3 was measured in whole cell
lysates, pretreated or not with either 10-7 M cytochalasin
B, or 10-7 M flutamide and then stimulated with 10-7 M
testosterone-HSA for the time periods indicated in the fig-
ure legends, using the Clontech ApoAlert® Caspase Color-
imetric Assay kit according to the manufacturers'
instructions. Caspase-3 activity was determined by incu-
bating lysates with a caspase-3 substrate (the peptide
DEVD conjugated to the chromophor p-nitroaniline) for
2 h at 37°C. The absorbance of each sample was measured
at 405 nm by using a 96-well colorimetric plate reader.
In vivo experiments
Experiments were carried out on 7-week old wild-type
Balb/c mice of either sex. The animals were housed under
controlled environmental conditions (22-24°C, 50-70%
humidity and a 12 h light/dark cycle). Throughout the
study the mice had free access to standard pelleted food
(C1310, Altromin, Heidenau, Germany) and tap water.
All animal experiments were conducted according to the
German law for the care and welfare of animals and were
approved by local authorities
Induction of colon carcinoma
Colon carcinoma was generated as described previously
[26]. In a first series of experiments, 7-week old Balb/c
mice (both male and female) were divided into two
groups, A (n = 5) and B (n = 7). Both groups underwent
carcinogenic treatment. At the age of 9 weeks animals
were subjected to three cycles of alternating administra-
tion of distilled water containing 30 g/L synthetic dextran
sulfate sodium (DSS; molelucar mass 5000 Da; Wako
Pure Chemical Industries, Led. Japan) for 7 days followed
by distilled water for subsequent 14 days after intraperito-
neal pretreatment with 20 mg/kg 1, 2-dimethylhydrazine
(DMH; Sigma-Aldrich Corp. St.Louis. MO. USA). Group B
mice received in addition to the carcinogenic treatment 5
mg/kg testosterone-HSA subcutaneously injected three
times per week throughout the study period. All mice were
sacrificed at the age of 20 weeks. After death, the entire
colorectum from the colorectal junction to the anal verge
was examined. Fresh specimens were placed in liquid
nitrogen and subsequently stored at -80°C for further
analysis. Then, the colon was opened longitudinally,
washed with PBS, and divided into three portions (proxi-
mal, middle and distal). After macroscopic inspection the
colon was fixed in a 40% g/L formaldehyde buffer solu-
tion (pH.7.4).
TUNEL assay
The colonic cancer tissue was cut to 8 μm frozen sections
from mouse colon tumors and subsequently fixed in 4%
paraformaldehyde for 30 min at room temperature. After
rinsing with PBS the samples were permeabilized in a
solution of 0.1% Triton X-100 in sodium citrate for 2 min.
Samples were washed with PBS and incubated in the
TUNEL reaction mix for 1 h at 37°C, according to the
manufacturer's instructions (Roche, Germany). Nuclei
were stained with DRAQ5™ (Biostatus Limited). Sections
were analysed by confocal microscopy.
Statistical analysis
Data are provided as means ± SEM, n  represents the
number of independent experiments. Data were tested for
significance using unpaired student's t-test, when two-
sample means were tested. Differences were considered
statistically significant when p-values were < 0.05. All sta-
tistical analysis was performed with GraphPad InStat ver-
sion 3.00 for Windows 95, GraphPad Software, San Diego
California USA, http://www.graphpad.com.Molecular Cancer 2009, 8:114 http://www.molecular-cancer.com/content/8/1/114
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Results
mAR expression in specimens of colon tumors and colon 
cancer cell lines
While analyzing paraffin blocks generated from in vivo
xenograft tumor tissues of various origins, we noticed sig-
nificant mAR expression in colon tumors. Specifically,
using testosterone-HSA-FITC fluorescent conjugates we
detected specific, FITC-related fluorescence in membrane
specimens of colon xenograft tumors generated from wild
type HCT116 cells (WCL2) (Fig. 1a,a') or HCT116 p53-/-
cells (MCL3) (Fig. 1d,d'). Conversely, no apparent stain-
ing could be identified in control tissues labeled with
HSA-FITC (Fig. 1c,f). Although the apparent visualization
of mAR staining in tissue preparations is restricted by
technical limitations, in cultured HCT116- (Fig. 1h) or in
Caco2-colon cells (Fig. 2A a,b) the membrane staining of
mARs was obvious by confocal laser scanning microscopy
using the fluorescent testosterone-HSA-FITC conjugate.
No apparent staining was evident in HSA-FITC-labeled
HCT116 or Caco2 cells (Fig. 1j, 2Ac,d). Interestingly, mAR
staining could not be detected in the membrane of the
non-transformed intestinal cell line IEC06 (Fig. 2B).
These staining experiments and the fact that testosterone-
HSA-FITC is an impermeable conjugate disclosed mAR
expression preferentially in colon cancer cell lines and
tumors.
Binding studies of membrane androgen receptors in colon 
cancer cells
To further study the specificity of mAR we performed sat-
uration binding of radiolabeled testosterone in mem-
brane preparations of Caco2 cells. As shown in fig. 2C,
determination of [3H] testosterone bound to Caco2 cells
at concentrations ranging from 1 to 100 nM revealed spe-
cific saturable binding. Scatchard analysis of the results
revealed high binding affinity for testosterone (KD 2.9
nM). The calculated Bmax was 22,37 fmol/mg protein.
Membrane preparations incubated with [3H] testosterone
in the presence of varying concentrations of DHT or estra-
diol (10-12 to 10-6 M), revealed a displacement of radiola-
beled testosterone by DHT (Fig. 2D), while estradiol
displaced radiolabeled testosterone with a significant
Membrane staining of mAR in colon tumors and colon cancer cells Figure 1
Membrane staining of mAR in colon tumors and colon cancer cells. Confocal laser scanning microscopic analysis of 
WCL2 (a-c) and MCL2 (d-f) colon tumor specimens and HCT116 cells (g-j) stained with testosterone-HSA-FITC, showing spe-
cific FITC related fluorescence at the cell membranes. Control staining with HSA-FITC showed no apparent membrane fluo-
rescence. Visualization of nuclei was evident by DAPI or TO-PRO-3 staining. Magnification, ×100.
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lower affinity, confirming the androgen selectivity of
these membrane receptors.
mAR activation triggered rapid actin and tubulin 
reorganization in colon cancer cells
Cytoskeleton reorganization is a prominent early func-
tional response of various cancer cells to steroid hor-
mones targeting membrane binding sites [3,8,19,27].
Accordingly to analyze the functional impact of mAR in
colon cancer we investigated rapid cytoskeleton modifica-
tions in Caco2 cells upon activation of mAR with testo-
sterone-HSA for various time intervals. Cellular actin
cytoskeleton dynamics were initially assessed by appro-
priate quantitative techniques as described in [25]. As
shown in fig. 3A, quantitative immunoblot analysis of Tri-
ton X-100-insoluble cytoskeletal pellets and correspond-
Membrane staining and binding assays of mAR in Caco-2 cells Figure 2
Membrane staining and binding assays of mAR in Caco-2 cells. A) Confocal laser scanning microscopic analysis of 
Caco2 cells (a-d) stained with testosterone-HSA-FITC, showing specific FITC related fluorescence at the cell membranes (a, b). 
No apparent membrane fluorescence was shown in control samples stained with HSA-FITC (c, d). Visualization of nuclei was 
evident by DRAQ5™ staining. Magnification, ×100. B) Confocal laser scanning microscopic analysis of IEC 06 cells (e-f) stained 
with testosterone-HSA-FITC, showing no apparent membrane fluorescence at the cell membrane. Visualization of nuclei was 
evident by DRAQ5™ staining. C) Saturation binding assay: Cell membranes were prepared as indicated in Materials and Meth-
ods at a final concentration of 1,2 mg/ml. They were incubated overnight at 4°C in the presence of seven concentrations of 
[3H] testosterone, which varied from 2 to 100 nM. KD and Bmax values for the membrane binding sites were determined from 
Scatchard plots (presented in inserts), based on saturation bindings. The figure represents the results of a typical experiment in 
triplicate. D) Displacement binding assay: Cell membranes were incubated with 5 nM of [3H] testosterone alone (Bo) or in the 
presence of the indicated concentrations of unlabelled steroids (DHT, estradiol), ranging from 10-12 to 10-6 M. Nonspecific 
binding was assayed by introducing 5 μM DHT. The figure (means of three different experiments performed in duplicate) 
presents the ratio of specific binding in the presence of the indicated concentrations of DHT (Bs) to the specific binding in the 
absence of DHT (Bo), Bs/Bo.
A C
D
a
10μm
b
10μm
c
10μm
d
10μm
                            
		


B 


                                         
10μm
e
10μm
f
                                         Molecular Cancer 2009, 8:114 http://www.molecular-cancer.com/content/8/1/114
Page 7 of 14
(page number not for citation purposes)
ing supernatants revealed a significant decrease of the
Triton-soluble (monomeric) over total actin ratio in
Caco2 cells treated with 10-7 M testosterone-HSA, indicat-
ing actin polymerization. This effect was evident 15 min
upon testosterone-HSA treatment and returned to nearly
control levels after 1-2 h (Fig. 3A). The quantitative data
were fully supported by confocal laser scanning micro-
scopic analysis showing redistribution of microfilamen-
tous structures and formation of stress fibers and
filopodia in testosterone-HSA treated cells (Fig. 3B). We
further analyzed tubulin cytoskeleton reorganization by
confocal laser scanning microscopy. A clear redistribution
of the microtubular network became evident in cells
treated with 10-7 M testosterone-HSA for 15 to 60 min
(Additional File 1).
mAR activation induced profound and specific pro-
apoptotic responses in colon cancer cells
To further analyze the functional status of mAR activation
in colon cancer cells, we assessed mAR-dependent pro-
apoptotic responses in Caco2 cells, as previously reported
in prostate cancer cells [8,9]. Annexin V fluorescence
staining of Caco2 cells treated with 10-7 M testosterone-
HSA for 24 h revealed clear evidence for induction of
apoptosis similar to the one observed in serum-starved
cells (Fig. 4A, compare b and c). The induction of apopto-
sis in Caco2 cells was further evident from the quantitative
APOPercentage apoptosis assay, which showed a clear tes-
tosterone-HSA-stimulated apoptotic response 12 and 24 h
post-treatment (Fig. 4B). Similar results were also
obtained in HCT116 cells (data not shown), while mAR
deficient (Fig 2B) non-transformed IEC06 intestinal cells
Modulation of the dynamic equilibrium between G- and Total actin in testosterone-HSA stimulated Caco2 cells Figure 3
Modulation of the dynamic equilibrium between G- and Total actin in testosterone-HSA stimulated Caco2 
cells. 24 h serum starved cells were stimulated with 10 -7 M androgen conjugate for the indicated time points. (A) Total and G- 
actin were measured by quantitative immunoblot analysis after Triton X-100 subcellular fractionation. Bars present the G/Total 
actin mean value ± SE of four independent duplicate experiments (** P < 0.01). (B) Cells were stained with rhodamine-phalloi-
din for filamentous actin and DRAQ5™ for nuclei. Confocal laser scanning microscopy analyzed samples. Magnification, ×100.
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did not responded to testosterone-HSA treatment, as indi-
cated by the APOPercentage apoptosis assay (Fig. 4C). In
line with these findings, testosterone-HSA induced time-
dependent activation of caspase-3 (Fig. 4D), indicating
the participation of caspases as executors in mAR-depend-
ent cell death. These effects were attributed to mAR activa-
tion and were independent of classical intracellular
androgen receptors, since both the apoptotic response
(Fig. 5A) and the caspase-3 activation (Fig. 5B) were not
inhibited in the presence of the anti-androgen flutamide.
In line with this, membrane-bound iAR could not be
detected in isolated membrane preparations of Caco2
cells by using specific iAR antibodies (Fig. 5C). In con-
trast, these membrane preparations were positive for the
expression of Na/K ATPase, a protein implicated in cellu-
lar ion homeostasis used as a positive membrane control
in this experiment. To establish the functional role of
actin reorganization in regulating the pro-apoptotic
responses induced by mAR, as previously reported for var-
ious cell systems [8,28,29], we assessed mAR-dependent
apoptosis and caspase-3 activation in the presence of anti-
actin drugs. As shown in Fig. 5A, B, in Caco2 cells pre-
treated with cytochalasin B, at a concentration (10-7M)
which blocks actin redistribution without exerting toxic
Pro-apoptotic effects of testosterone-HSA in Caco2 cells Figure 4
Pro-apoptotic effects of testosterone-HSA in Caco2 cells. Caco2 cells stimulated with 10-7 M androgen conjugate for 
the indicated time periods. (A) Cells were stained with Annexin V and visualized by confocal laser scanning microscopy. Magni-
fication, ×400. (B) Quantitative APO-Percentage apoptosis assay of testosterone-HSA stimulated Caco2 cells according to the 
manufacturer's instructions. Bars present the mean OD measured at 550 nm (** P < 0.01, N = 4). (C) Non-transformed intes-
tinal IEC 06 cells were exposed to 10-7 M testosterone-HSA for 24 and 48 hours. No apoptoric response was evident by the 
APOPercentage apoptosis assay. Cells serum starved for 24 hours served as positive control for apoptosis. Bars present the 
mean OD measured at 550 nm, N = 3. (D) Caspase-3 activity was measured at 405 nm in lysates derived from testosterone-
HSA treated cells in the presence, or absence of caspase-3 inhibitor DEVD-fmk for the indicated time periods and then incu-
bated with the caspase-3 substrate DEVD conjugated to the chromophore pNA according to the manufacturer's instructions 
(** P < 0.01, * P < 0.05, N = 4).
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effects [30], the mAR-induced apoptotic response (Fig.
5A) and caspase-3 activation (Fig. 5B) were abolished.
These results indicate that actin redistribution is a manda-
tory step for the apoptotic response of mAR-stimulated
colon cancer cells. We further evaluated the steroid-hor-
mone specificity of the mAR-induced apoptotic responses
by using non-conjugated testosterone and estradiol deriv-
atives. As shown in fig. 5A, free estradiol could not gener-
ate any apoptotic response, while free DHT clearly
showed activity. Finally, considering the estimated KD of
2.9 nM for mAR (Fig. 2B, C), we further performed titra-
tion experiments using a wide range of testosterone-HSA
and free DHT concentrations (10-7 M to 10-10 M) in the
presence or absence of caspase inhibitor respectively.
These experiments indicate that even in the nM range the
testosterone conjugate and DHT have very similar pro-
apoptotic effects (Fig. 6). These effects were abolished in
the presence of the caspase inhibitor (Fig. 6).
mAR activation by testosterone-HSA was followed by 
extensive reduction of tumor incidence in vivo
The findings provided so far established that mAR activa-
tion results in colon cancer cell regression in vitro. Thus,
we aimed to further evaluate the in vivo effects of albumin-
Pro-apoptotic effects of testosterone-HSA, DHT and estradiol in the absence or presence of inhibitors in Caco2 cells Figure 5
Pro-apoptotic effects of testosterone-HSA, DHT and estradiol in the absence or presence of inhibitors in 
Caco2 cells. (A) Quantitative APOPercentage apoptosis assay of testosterone-HSA, DHT or estradiol stimulated Caco2 cells 
and in the presence/absence of cytochalasin B (Cyto B) or flutamide. Cells were exposed to 10-7 M testosterone-HSA, DHT or 
estradiol for 24 hours and pro-apoptoric responses were assessed by the APOPercentage apoptosis assay. Equally, cells pre-
treated or not with 10-7 M Cyto B or flutamide, were exposed to testosterone-HSA for 24 hours. Cells serum starved for 
comparable periods of time served as a positive control for apoptosis. Bars present the mean OD measured at 550 nm (** P < 
0.01, N = 4). (B) Cells were pre-treated or not with Cyto B or flutamide for 1 h and then exposed or not to 10-7 M testoster-
one-HSA for 4 h, lysed and incubated with the caspase-3 substrate DEVD conjugated to the chromophore pNA according to 
the manufacturer's instructions. Caspase-3 activity was measured at 405 nm (** P < 0.01, N = 4). (C) Immunoblot analysis for 
iAR expression in membrane preparations. Membranes were isolated as described in Materials and Methods and subjected to 
immunoblot analysis using a specific iAR antibody, and subsequently a Na+/K+ ATPase or actin antibody as a positive/negative 
control respectively.
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conjugated androgens in colon cancer animal models. To
this end, we first estimated the expression of mAR in
colon tumors generated in Balb/c mice. As shown in fig.
7A and fig. 7B, using testosterone-HSA-FITC we detected
specific, FITC-related fluorescence in membrane speci-
mens of Balb/c mice colon tumors (Fig. 7Aa, a'), while no
apparent staining could be identified in tissues labeled
with HSA-FITC (Fig. 7Ab). Interestingly, mAR staining
was very low in healthy colon tissue specimens of Balb/c
mice (Fig. 7B) further supporting earlier findings pointing
to cancer tissue specificity of mAR [31]. Having a clear
indication for mAR-expression, we assessed the 12-week
tumor incidence of colon tumors generated in Balb/c mice
by chemical carcinogenesis (see Materials and Methods)
in the presence or absence of continuous testosterone-
HSA treatment. The animals used for these studies were
divided in two groups comprising of 5 and 7 animals
respectively. One group (7 animals) was treated subcuta-
neously (3 times/week for 12 weeks) with 5 mg/kg testo-
sterone-HSA, whereas the other group (5 animals)
remained untreated. The results (Fig. 7C) show that testo-
sterone-HSA treatment produced a clear and significant
reduction of tumor incidence by 65%. The histological
analysis of tumors by TUNEL assay confirmed that apop-
totic cells were present in significant numbers predomi-
nantly in the tumors of animals treated with testosterone-
HSA (Fig. 7D, middle panels), while they were signifi-
cantly less either in the non-treated animals (Fig. 7D, right
panels), or in healthy tissues of treated animals (Fig. 7D,
left panels). These results collectively show that mAR is a
functional and specific target that may be used for the
selective elimination of colon cancer cells in vivo.
Discussion
In the present work we provide strong experimental evi-
dence that membrane androgen receptors are expressed in
colon tumors. Using tissue specimens derived from colon
tumors and established colon tumor cell lines we showed
that colon cancer cells predominantly express functional
mAR, while mAR expression is undetectable in healthy
mouse colon tissues or non-transformed intestinal cells.
Moreover, membrane-impermeable testosterone albumin
conjugates induced a) profound and rapid actin and tubu-
lin reorganization, and b) considerable apoptosis via acti-
vation of the pro-apoptotic executor caspase-3. The
observed mAR-activated effects were specific for testoster-
one and testosterone conjugates, since other steroid hor-
mones such as estradiol did not exhibit any pro-apoptotic
activity.
Dose-dependent analysis of testosterone-HSA and DHT induced apoptosis in Caco2 cells in the absence or presence of cas- pase-3 inhibitor Figure 6
Dose-dependent analysis of testosterone-HSA and DHT induced apoptosis in Caco2 cells in the absence or 
presence of caspase-3 inhibitor. Quantitative APOPercentage apoptosis assay of testosterone-HSA and DHT stimulated 
Caco2 cells. Cells were exposed to 10-7 M to 10-10M testosterone-HSA and DHT respectively in the presence or absence of 
the caspase-3 inhibitor DEVD-fmk for 24 hours. The pro-apoptoric response was assessed by the APOPercentage apoptosis 
assay. Cells serum starved for comparable period of time served as a positive control for apoptosis. Bars indicate the mean OD 
measured at 550 nm ± SE of three independent experiments performed in triplicates, normalized versus the untreated control 
(serum supplemented cells) and presented as percentage (%) of the untreated serum supplemented control cells taken as 100 
(*P < 0.05, N = 3).
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Our binding studies, including radioligand binding exper-
iments, Scatchard analysis and displacement assays,
attributed receptor properties to the identified testoster-
one membrane binding sites. Moreover, they showed
high affinity and specificity for testosterone, as indicated
by the displacement of radiolabeled testosterone by DHT
but not by estradiol. The calculated KD (2.9 nM) is very
close to that reported for LNCaP and DU145 prostate can-
cer cells [3,7]. Others also obtained similar results in dif-
ferent cell systems [32]. These data collectively indicate
that these membrane-binding sites may potentially repre-
sent a specific membrane receptor for androgens. Hitherto
the exact molecular identity of mAR remained elusive.
According to the experimental evidence provided so far,
mAR may represent either (I) a pool of iAR targeted to the
plasma membrane and/or associated membrane struc-
tures (e.g. lipid rafts or caveolae) mediating rapid andro-
gen effects in the absence of transcriptional activity [33] or
(II) an unknown G-protein-coupled receptor (GPCR) (or
a receptor associated with a GPCR) triggering a variety of
In vivo testosterone-HSA effects on tumor incidence in BALB/c mice Figure 7
In vivo testosterone-HSA effects on tumor incidence in BALB/c mice. A) Confocal laser scanning microscopic analysis 
of BALB/c colon tumor frozen sections stained with testosterone-HSA-FITC (a, a'), showing specific FITC related fluorescence 
at the cell membranes. No apparent membrane fluorescence was shown in control samples stained with HSA-FITC (b). Visual-
ization of nuclei was evident by DRAQ5™ staining. Magnification, ×100. (B) Confocal laser scanning microscopic analysis of 
BALB/c colon tumor and healthy frozen sections stained with testosterone-HSA-FITC, showing specific FITC related fluores-
cence at the cell membranes of tumor sections (a). Very low membrane fluorescence was shown in healthy colon sections 
stained with testosterone-HSA-FITC (b). Visualization of nuclei was evident by DRAQ5™ staining. Magnification, ×100. (C) 
Arithmetic means ± SEM of colonic tumor incidence in BALB/c mice. Following treatment with the carcinogenic drug 1, 2-
dimethylhydrazine followed by dextrane sodium sulphate, one group (7 animals) was treated subcutaneously (3 times/week for 
12 weeks) with 5 mg/kg testosterone-HAS (black bar), whereas the other group (5 animals) remained untreated (white bar). # 
indicates significant difference between both groups (# P < 0.01). (D) After treatment, the colonic cancer and healthy tissue 
was cut to 8 μm frozen sections and fragmented DNA was assessed by TUNEL assay according to the manufacturer's instruc-
tions. Confocal laser scanning microscopy analyzed samples. Magnification, ×100.
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iAR-independent signaling cascades [17,34,35]. Our
results, showing that iAR a) could not be detected in
membrane preparations of colon cancer cells (Fig. 5C)
and b) that testosterone-HSA effects were manifested even
in the presence of the anti-androgen flutamide (Fig 5A, B),
imply that the molecular identity of mAR is probably not
identical with iAR, targeted to the plasma membrane.
They are in line with previous reports for LNCaP and DU-
145 prostate cancer cells [7,8]. Although these findings
argue against the hypothesis that iAR is expressed in the
plasma membrane, only the identification and/or molec-
ular cloning of this new receptor can define his molecular
identity.
The results from this and other studies indicated that
membrane androgen receptors are predominantly
expressed in tumor cells ([31] and Fig. 2B, 7B). In addi-
tion, activation of these receptors triggers pro-apoptotic
responses. One possible rationalization for the expression
of those receptors is that tumor cells may compensate
mAR-dependent apoptosis by over-expressing anti-apop-
totic proteins or other compensatory mechanisms that
collectively protect against mAR-dependent apoptosis.
Previous reports support this assumption: Indeed, iAR-
deficient DU145 human prostate cancer cells were shown
to overexpress the pro-survival PI-3K/Akt pathway, which
was down-regulated following long-term mAR activation
[9]. In addition, the FAK/PI3K pathway was constitutively
activated in DU145 cells and mAR activation was unable
to further alter the short-term phosphorylation levels of
those kinases [8], while long term activation induced sig-
nificant de-phosphorylation [9].
The connection between actin cytoskeleton components
and androgen signaling has attracted specific interest in
recent years (for a review see [36]). Actin dynamics seem
to be crucial for apoptotic responses [28,29]. The findings
in our present work further underscored the key role of
actin cytoskeleton rearrangements in regulating apopto-
sis. Indeed, it was clearly shown that actin (and tubulin)
reorganization represent major early events following
mAR activation by testosterone-HSA. Moreover, early
blockade of actin rearrangement by depolymerizing drugs
e.g. cytochalasin B, virtually abrogated the pro-apoptotic
responses (Fig. 5A, B). The involvement of the early actin
rearrangement in mediating the late apoptotic responses
was addressed in earlier studies in prostate cancer cells. In
these studies it was shown that inhibition of either up-
stream or down-stream signals regulating early actin
polymerization blocked the late activation of NF-κB and
FasL signaling [9]. Although the pro-apoptotic signaling
was not addressed in the present study we hypothesize
that the actin reorganization is an early functional step in
the pro-apoptotic response. These findings, which are in
close agreement with similar results reported recently in
prostate cancer cells treated with testosterone albumin
conjugates [8,9], further emphasize the functional cross-
talk between cytoskeleton rearrangements and regulation
of apoptosis [28,29].
Recent studies using mouse xenografts have shown that a
testosterone-albumin conjugate (testosterone-BSA)
induced potent apoptotic regression of prostate tumors in
vivo [7]. In addition, testosterone-BSA was also reported to
potentiate the paclitaxel-mediated cytotoxicity both in
vitro  and  in vivo [19]. Based on these reports, on the
expression patterns indicating predominant mAR mani-
festation in cancer cells (Fig. 1, 2A, 2B and 7A, 7B) and on
the functional analysis of those receptors in colon cancer
specimens and cell lines (Fig. 4, 5, 6), we evaluated their
potential biological role as drug targets in colon tumors in
vivo. Interestingly, the chemically-induced colon tumors
were reduced by 65% in the testosterone-HSA-treated ani-
mals. Most probably this effect was due to the apoptotic
regression of tumor cells as indicated by the TUNEL assay
(Fig. 7D, middle panel). These results point out clearly
that activation of mAR by testosterone-HSA significantly
affects the incidence of colon tumors in vivo. Interestingly,
mAR is strongly expressed in tissues derived from p53-
deficient xenograft tumors (Fig. 1d, d'). Since p53 is a fre-
quently inactivated gene in tumors, it is interesting to
hypothesize that mAR activation may result in eradication
of p53 tumors in vivo. In addition, the detailed analysis of
mAR expression in normal and cancer colon tissues iso-
lated from mice revealed clearly mAR over-expression in
tumor tissues, while in healthy specimens and non trans-
formed intestinal IEC06 cells mAR expression was unde-
tectable (Fig. 2B, 7B). These findings support the notion
that most probably normal cells will not respond to testo-
sterone-HSA treatment, a conclusion supported by the
TUNEL assay (Fig. 7D, left panels), which indicated very
low apoptotic response of normal tissues to testosterone-
HSA treatment, as well as from the failure of any pro-
apoptotic response in testosterone-HSA treated IEC06
cells (Fig. 4C). Despite the fact that additional experi-
ments are required for the detailed evaluation of mAR-
dependent biological effects in colon cancer, our findings
fully enforce the potential significance of the recently pos-
tulated notion [17] that mAR may represent a novel and
specific tumor target.
In conclusion, the results presented here add a clear and
significant piece of evidence to the potential anti-tumori-
genic role of membrane androgen receptors. They indicate
that a) functional mAR are expressed not only in hor-
mone-dependent tumors but also in colon tumors, b)
their activation through steroid albumin conjugates
induces potent pro-apoptotic responses regulated by
cytoskeletal rearrangements, and c) these receptors may
represent specific targets for the development of novelMolecular Cancer 2009, 8:114 http://www.molecular-cancer.com/content/8/1/114
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drugs, since their activation drastically regresses tumor
growth and tumor incidence in vivo. Additional experi-
ments are now required for the identification of the
molecular identity of these receptors.
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